Literature DB >> 8275455

The application of fluorescent in situ hybridization to detect Mbcr/abl fusion in variant Ph chromosomes in CML and ALL.

G W Dewald1, C R Schad, E R Christensen, A L Tiede, A R Zinsmeister, J L Spurbeck, S N Thibodeau, S M Jalal.   

Abstract

We investigated the usefulness of fluorescent in situ hybridization with different-colored major breakpoint cluster region (Mbcr) and Abelson oncogene (abl) probes in clinical practice. In standard Ph chromosomes with a Mbcr breakpoint, these probes produced a fusion of Mbcr and abl signals that was visible in interphase and metaphase cells. The normal range for apparent Mbcr/abl fusion signals in interphase nuclei was established in bone marrow from 25 normal controls. We tested the probes on 35 bone marrow specimens from five normal subjects and 29 patients with various kinds of Ph chromosomes and chronic myelogenous leukemia or acute lymphocytic leukemia. This method produced Mbcr/abl fusion signals in patients with a standard Ph chromosome, simple or complex variants of Ph chromosomes, and "Ph-negative chronic myelogenous leukemia." In metaphase cells of patients with acute lymphocytic leukemia, this method established Ph chromosomes with minor bcr (mbcr) breakpoints. Fluorescent in situ hybridization is a relatively inexpensive and rapid method. When this method is used in conjunction with conventional chromosome analysis, the cytogeneticist can combine the power of complete karyotype studies and the resolution of molecular techniques for patients suspected of having a Ph chromosome.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8275455     DOI: 10.1016/0165-4608(93)90196-s

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  11 in total

Review 1.  Clinical applications of BCR-ABL molecular testing in acute leukemia.

Authors:  Amgad L Nashed; Kathleen W Rao; Margaret L Gulley
Journal:  J Mol Diagn       Date:  2003-05       Impact factor: 5.568

2.  Detection of the BCR-ABL gene by interphase fluorescence in situ hybridization (iFISH) in chronic myelogenous leukemia patients after hemopoietic stem cell transplantation: the feasibility of iFISH monitoring of therapeutic response in peripheral blood.

Authors:  You Kyoung Lee; Dong Wha Lee; Yoo Li Kim; Seok Lee; Chang Ki Min; Yoo-Jin Kim; Il-Hoan Oh; Tai-Gyu Kim; Chun Choo Kim; Dong-Wook Kim
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

3.  Guidance for fluorescence in situ hybridization testing in hematologic disorders.

Authors:  Daynna J Wolff; Adam Bagg; Linda D Cooley; Gordon W Dewald; Betsy A Hirsch; Peter B Jacky; Kathleen W Rao; P Nagesh Rao
Journal:  J Mol Diagn       Date:  2007-04       Impact factor: 5.568

4.  Pilot studies for proficiency testing using fluorescence in situ hybridization with chromosome-specific DNA probes: a College of American Pathologists/American College of Medical Genetics Program.

Authors:  G W Dewald; A R Brothman; M G Butler; L D Cooley; S R Patil; I A Saikevych; N R Schneider
Journal:  Arch Pathol Lab Med       Date:  1997-04       Impact factor: 5.534

Review 5.  Colour thresholding in video imaging.

Authors:  C D Fermin; S Degraw
Journal:  J Anat       Date:  1995-06       Impact factor: 2.610

Review 6.  Cytogenetic and FISH studies in myelodysplasia, acute myeloid leukemia, chronic lymphocytic leukemia and lymphoma.

Authors:  Gordon W Dewald
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

7.  Molecular cytogenetic study of derivative chromosome 9 deletion in chronic myeloid leukemia patients.

Authors:  Ayda Bennour; Ines Ouahchi; Yosra Ben Youssef; Monia Zaier; Mohamed Adnéne Laatiri; Imed Harrabi; Balkis Meddeb; Moez Elloumi; Abderrahim Khelif; Ali Saad; Halima Sennana
Journal:  Med Oncol       Date:  2011-04-03       Impact factor: 3.064

8.  Derivative chromosome 9 deletions in chronic myeloid leukaemia: interpretation of atypical D-FISH pattern.

Authors:  T S K Wan; S K Ma; W Y Au; L C Chan
Journal:  J Clin Pathol       Date:  2003-06       Impact factor: 3.411

9.  [Regression of the Philadelphia chromosome (bcr/abl)-positive myelo- and megakaryopoiesis after Imatinib (STI571) therapy in chronic myelogenous leukemia (CML)].

Authors:  J Thiele; H M Kvasnicka; E Varus; S Kriener; K Engels; P Staib; E S Ollig; M Griesshammer; C F Waller; H Pfeifer; A Schmitt-Gräff
Journal:  Pathologe       Date:  2004-11       Impact factor: 1.011

10.  Correlation between BCR-ABL expression and tumor burden is restricted to the transition from minor to major cytogenetic response in interferon treated CML patients.

Authors:  László Kereskai; János A Vass; Mária Kneif; László Pajor
Journal:  Pathol Oncol Res       Date:  2003-10-07       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.